Schmitt T, Prades J, Pinto N, Puel G, Barbet N, Calloc'h F
Service de radiothérapie, CHU de Bellevue, Saint-Etienne, France.
Bull Cancer Radiother. 1996;83(2):79-85.
Treatment by surgery and postoperative radiotherapy is classical for patients with locally advanced oropharyngeal carcinoma. The poor prognosis of these tumors is associated with the frequency of locoregional relapses, and the survival of the patients treated is more limited according to the initial degree of tumoral involvement of the base of the tongue, which is a critical zone: at this level, the surgical resection must not be too large for a good preservation of the function of the tongue; high doses of radiotherapy are also required here for a fair local tumor control. Intraoperative Radiotherapy (IORT) may be available for delivery of high boosting doses of radiotherapy locally in this target volume. Between March 1988 and March 1992, 39 patients were treated for T3-T4 locally advanced oropharyngeal carcinoma, with 1/4 to 1/2 of the base of the tongue involved; 30 patients were treated for a first localization. Surgery was done by transmaxillary buccopharyngectomy (followed by vascularized myocutaneous flap) for 31 patients with lateral tumors; for 8 patients with median tumor (valleculae), either a conservative susglottic laryngectomy (5 patients) or a total laryngectomy was indicated. Patients treated for the first time underwent also a bilateral node dissection. IORT delivered 20 Gy in the target volume of the resected base of the tongue (prescribed at 90% isodose depth) by the mean of an electron beam of 6 to 13 MeV, with a collimator of 4 or 5 cm of inner diameter. Postoperative radiotherapy was indicated for all patients treated with a first localization. After a minimal follow-up of 6 months, the global survival of 28 patients treated for their first localization was 49% at more than 3 years; 64% of patients treated were locally free of disease. In the same delay, and according to the quality of the surgical resection, the survival of patients treated was 67% and 58%, respectively, if non pathological level of resection was beyond 2 mm, or unless 2 mm from the tumor limit. No complication directly related to IORT was noted. These therapeutic results demonstrate the validity of IORT as a part of a radiosurgical treatment indicated for patients with locally advanced oropharyngeal carcinomas. A longer follow-up of patients treated with a first oropharyngeal tumor is warranted for confirmation of the gain on survival observed.
对于局部晚期口咽癌患者,手术及术后放疗是经典的治疗方法。这些肿瘤预后较差与局部区域复发的频率相关,并且根据舌根这一关键区域肿瘤受累的初始程度,接受治疗患者的生存期更有限:在此水平,为了良好保留舌功能,手术切除范围不宜过大;为了实现较好的局部肿瘤控制,此处也需要高剂量放疗。术中放疗(IORT)可用于在此靶区内局部给予高剂量的放疗增敏。1988年3月至1992年3月期间,39例T3 - T4局部晚期口咽癌患者接受治疗,其中1/4至1/2的舌根受累;30例患者为首次发病。31例侧方肿瘤患者采用经上颌颊咽切除术(随后行带血管蒂肌皮瓣修复);8例中位肿瘤(会厌谷)患者,5例行保守性声门上喉切除术,3例行全喉切除术。首次治疗的患者还进行了双侧淋巴结清扫。通过6至13 MeV的电子束,使用内径为4或5 cm的准直器,在切除的舌根靶区内给予IORT 20 Gy(规定在90%等剂量深度)。所有首次发病接受治疗的患者均需进行术后放疗。经过至少6个月的随访,28例首次发病接受治疗的患者3年以上的总生存率为49%;64%的治疗患者局部无疾病。在同一时期,根据手术切除质量,若切除切缘无病理残留超过2 mm或距肿瘤边界小于2 mm,接受治疗患者的生存率分别为67%和58%。未观察到与IORT直接相关的并发症。这些治疗结果证明了IORT作为局部晚期口咽癌患者放射外科治疗一部分的有效性。有必要对首次口咽肿瘤治疗的患者进行更长时间的随访,以确认观察到的生存获益。